G Viale Selected Research

G Viale Research Topics

Disease

74	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2000
54	Neoplasms (Cancer) 04/2024 - 01/2000
19	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2001
10	Triple Negative Breast Neoplasms 11/2022 - 01/2011
9	Carcinoma (Carcinomatosis) 09/2009 - 01/2000
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017 - 12/2005
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 02/2003
3	Adenocarcinoma 04/2007 - 03/2001
3	Lymphatic Metastasis 03/2007 - 06/2000
2	Lung Neoplasms (Lung Cancer) 04/2024 - 08/2009
2	Carcinogenesis 12/2022 - 06/2000
2	Pathologic Complete Response 01/2022 - 12/2016
2	Residual Neoplasm 01/2017 - 02/2015
2	Hemangiosarcoma (Angiosarcoma) 05/2015 - 07/2014
2	Ductal Carcinoma 10/2013 - 08/2001
2	Adenosquamous Carcinoma 02/2003 - 03/2001
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2003 - 03/2001
2	Lymphoma (Lymphomas) 11/2001 - 08/2000
2	Epstein-Barr Virus Infections 10/2001 - 06/2000
1	Brain Stem Neoplasms (Brain Stem Tumor) 06/2021
1	Heart Failure 01/2018
1	Cardiotoxicity 01/2018
1	Insulin Resistance 11/2013
1	Necrosis 04/2013
1	Atrial Fibrillation 08/2012

Drug/Important Bio-Agent (IBA)

17	Estrogen ReceptorsIBA 10/2020 - 08/2000
13	Hormones (Hormone)IBA 04/2024 - 08/2000
13	Progesterone Receptors (Progesterone Receptor)IBA 03/2013 - 01/2000
12	human ERBB2 proteinIBA 04/2024 - 04/2008
10	Phenobarbital (Luminal)FDA Link 09/2020 - 10/2010
9	Tamoxifen FDA LinkGeneric 12/2015 - 05/2007
7	Methotrexate (Mexate)FDA LinkGeneric 01/2024 - 01/2002
7	Biomarkers (Surrogate Marker)IBA 12/2022 - 11/2004
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2024 - 01/2002
6	Letrozole (Femara)FDA LinkGeneric 10/2021 - 05/2007
5	Proteins (Proteins, Gene)FDA Link 05/2015 - 06/2000
5	Fluorouracil (Carac)FDA LinkGeneric 10/2011 - 11/2001
4	ErbB Receptors (EGF Receptor)IBA 04/2024 - 04/2015
4	Trastuzumab (Herceptin)FDA Link 01/2018 - 12/2007
4	Hematoxylin (Haematoxylon)IBA 02/2015 - 06/2001
4	Eosine Yellowish-(YS) (Eosin)IBA 02/2015 - 06/2001
4	Messenger RNA (mRNA)IBA 10/2007 - 06/2000
4	Monoclonal AntibodiesIBA 03/2001 - 01/2000
3	Estrogens (Estrogen)FDA Link 10/2021 - 01/2000
3	AnthracyclinesIBA 01/2018 - 11/2001
3	Aromatase InhibitorsIBA 10/2011 - 05/2007
3	Vinorelbine (Navelbine)FDA LinkGeneric 11/2008 - 11/2001
3	Indicators and Reagents (Reagents)IBA 10/2007 - 06/2000
2	trastuzumab deruxtecanIBA 04/2024 - 04/2024
2	Immunoconjugates (Immunoconjugate)IBA 04/2024 - 01/2023
2	LigandsIBA 10/2018 - 06/2000
2	taxaneIBA 01/2018 - 11/2008
2	Insulin-Like Growth Factor I (IGF-1)IBA 03/2014 - 06/2000
2	Docetaxel (Taxotere)FDA Link 05/2013 - 11/2008
2	Goserelin (Zoladex)FDA Link 10/2011 - 02/2010
2	fascinIBA 04/2007 - 02/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2006 - 01/2002
2	Cisplatin (Platino)FDA LinkGeneric 10/2003 - 11/2001
2	Keratins (Keratin)IBA 12/2001 - 06/2001
2	Protein Isoforms (Isoforms)IBA 08/2001 - 01/2000
2	Coloring Agents (Dyes)IBA 08/2001 - 10/2000
2	AntibodiesIBA 08/2001 - 06/2000
1	Ado-Trastuzumab EmtansineIBA 04/2024
1	telisotuzumab vedotinIBA 04/2024
1	Surface Antigens (Surface Antigen)IBA 04/2024
1	sacituzumab govitecanIBA 04/2024
1	patritumab deruxtecanIBA 04/2024
1	Serine (L-Serine)FDA Link 12/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 12/2022
1	CarbonIBA 12/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2022
1	AntimetabolitesIBA 12/2022
1	Poly Adenosine Diphosphate RiboseIBA 12/2022
1	olaparibIBA 12/2022
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 12/2022
1	atezolizumabIBA 01/2022
1	pertuzumabIBA 01/2018
1	Diphosphonates (Bisphosphonates)IBA 01/2017
1	Sex Hormone-Binding GlobulinIBA 03/2014
1	C-Reactive ProteinIBA 03/2014
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 11/2013
1	Metformin (Glucophage)FDA LinkGeneric 11/2013
1	Progesterone FDA LinkGeneric 10/2013
1	Androgen Receptors (Androgen Receptor)IBA 09/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2013
1	Quinidine (Chinidin)FDA LinkGeneric 08/2012
1	Retinoic Acid Receptor alphaIBA 05/2011
1	Promyelocytic Leukemia ProteinIBA 05/2011

Therapy/Procedure

27	Therapeutics 04/2024 - 12/2003
26	Drug Therapy (Chemotherapy) 12/2022 - 08/2000
10	Radiotherapy 12/2017 - 08/2006
8	Neoadjuvant Therapy 01/2022 - 01/2007
6	Adjuvant Chemotherapy 01/2024 - 11/2008
2	Immunotherapy 11/2022 - 01/2017
2	Segmental Mastectomy (Lumpectomy) 12/2017 - 10/2003
2	Mastectomy (Mammectomy) 09/2009 - 12/2005
2	Combination Drug Therapy (Combination Chemotherapy) 08/2008 - 12/2006
2	Lymph Node Excision (Lymph Node Dissection) 08/2006 - 09/2001
2	ViFuP protocol 10/2003 - 11/2001
1	Maintenance Chemotherapy 12/2022